

NOTON K. DUTTA, PH.D.: CURRICULUM VITAE

[Signature] _____
[Typed name] **Noton Kumar Dutta**

September 23, 2019

DEMOGRAPHIC INFORMATION

Current Appointment

09/2015-present **Research Associate** (non-tenure-track faculty), Johns Hopkins University School of Medicine

Personal Data

Office Address:

Center for Tuberculosis Research

Division of Infectious Diseases

Department of Medicine

Johns Hopkins University

1503 E Jefferson Street, Room # 105

Baltimore, MD 21287-0018

Cell: 985-590-8124

Tel: (410) 502-0023

Fax: (410) 614-8173

E-mail: ndutta1@jhmi.edu

Residential Status: Permanent resident of the United States of America as Alien of Extraordinary ability, 2014
Eligible to apply for US citizenship any time after May 15, 2019.

EDUCATION, TRAINING (in chronological order)

Year	Degree/Certificate, Institution (state, country), Discipline, Performance
------	---

Undergraduate

1994-1997	B.Sc., Visva Bharati University (India), Life Science, 1 st Class (62%)
-----------	--

Postgraduate

1997-1999	M.Sc., Visva Bharati University (India), Life Science, 1 st Class (68%)
-----------	--

Diploma

1999-2000	B.Ed., Visva Bharati University (India), Education, 1 st Class (69%)
-----------	---

Doctoral/graduate

2000-2004	Ph.D., Jadavpur University (India), Medical Microbiology
-----------	--

Postdoctoral

2006-2008	Fellowship, Seoul National University (Seoul, Korea), Laboratory Animal Medicine
-----------	--

2008-2011	Fellowship, Tulane National Primate Research Center (LA, USA), Bacteriology
-----------	---

2011-2015	Fellowship, Johns Hopkins University (MD, USA), Infectious Diseases
-----------	---

PROFESSIONAL EXPERIENCE (in chronological order, earliest first, including academic appointments)

Dates	Position	Institution
2000-2001	Research Trainee	Dept. of Microbiology, Parasitology, Calcutta University College of Medicine (Presently Institute of Postgraduate Medical Education, Research, SSKM Hospital), Kolkata, India.
2001-2004	Project Scientist	Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
2004-2006	Lecturer	Department of Microbiology, Institute of Genetic Engineering, University of

		Kalyani, (Presently affiliated to West Bengal University of Technology), Kolkata, India.
2006-2008	Postdoctoral Fellow	Laboratory Animal Medicine, College of Veterinary Medicine, Seoul National University, Seoul, Korea.
2008-2011	Postdoctoral Fellow	Tulane National Primate Research Center, Covington, LA, USA.
2011- 2015	Postdoctoral Fellow	Johns Hopkins University School of Medicine, Baltimore, MD, USA.

RESEARCH ACTIVITIES

Peer Reviewed Original Science Publications

Published papers (Total 72): Journal Impact Factor total: 252.85; Citation Indices: citations 2004, h-index 27, i10-index 53 (Source: Google scholar, Research Gate)

Original Research

1. Ray R, Das AK, **Dutta NK**, Chakrabarty AN, Chaudhuri BN, Seth S, Dastidar SG: Potentiality of a new compound for *in vitro* differentiation between halophilic and non-halophilic vibrios. *Indian Journal of Experimental Biology* 40, 2002; 220-222. Impact factor 1.475, Cited 1 time.
2. Dastidar SG, Annadurai A, Kumar KA, **Dutta NK**, Chakrabarty AN: Evaluation of a synergistic combination between the non-antibiotic microbicides diclofenac and trifluoperazine. *International Journal of Antimicrobial Agents* 21(6), 2003; 599-601. Impact factor 4.253, Cited 15 times.
3. Kumar KA, Ganguly K, Mazumdar K, **Dutta NK**, Dastidar SG, Chakrabarty AN: Amlodipine: a cardiovascular drug with a powerful antimicrobial property. *Acta Microbiologica Polonica* 52(3), 2003; 285-292. Impact factor 1.239, Cited 44 times.
4. Mazumdar K, Ganguly K, Kumar KA, **Dutta NK**, Chakrabarty AN, Dastidar SG: Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride. *Microbiological Research* 158(3), 2003; 259-264. Impact factor 2.777, Cited 33 times.
5. Sarkar A, Kumar KA, **Dutta NK**, Chakraborty P, Dastidar SG: Evaluation of *in vitro* and *in vivo* antibacterial activity of dobutamine hydrochloride. *Indian Journal of Medical Microbiology* 21(3), 2003; 172-178. Impact factor 1.157, Cited 57 times.
6. **Dutta NK**, Dastidar SG, Kumar KA, Mazumdar K, Ray R, Chakrabarty AN: Antimycobacterial activity of the antiinflammatory agent diclofenac sodium, and its synergism with streptomycin. *Brazilian Journal of Microbiology* 35(4), 2004; 316-323. Impact factor 1.81, Cited 34 times.
7. **Dutta NK**, Kumar KA, Mazumdar K, Dastidar SG, Ray R, Chakrabarty AN: *In vitro* and *in vivo* antimycobacterial activity of antiinflammatory drug, diclofenac sodium. *Indian Journal of Experimental Biology* 42, 2004; 922-927. Impact factor 1.475, Cited 22 times.
8. Mazumdar K, **Dutta NK**, Dastidar SG, Motohashi N, Shirataki Y: Phytochemical isoflavones against diabetic foot bacteria. *Oriental Pharmacy and Experimental Medicine* 4(4), 2004; 261-266. Cited 2 times.
9. Dastidar SG, Manna AK, Kumar KA, Mazumdar K, **Dutta NK**, Chakrabarty AN, Motohashi N, Shirataki Y: Studies on the antibacterial potentiality of isoflavones. *International Journal of Antimicrobial Agents* 23, 2004; 99-102. Impact factor 4.253, Cited 63 times.
10. Kumar KA, Mazumdar K, **Dutta NK**, Karak P, Dastidar SG, Ray R: Evaluation of synergism between the aminoglycoside antibiotic streptomycin and the cardiovascular agent amlodipine. *Biological & Pharmaceutical Bulletin* 27(7), 2004; 1116-1120. Impact factor 1.694, Cited 39 times.
11. **Dutta NK**, Mazumdar K, Dastidar SG, Chakrabarty AN, Shirataki Y, Motohashi N: *In vitro* and *in vivo* antimycobacterial activity of an antihypertensive agent methyl-L-DOPA. *In Vivo* 19, 2005; 539-546. Impact factor 1.116, Cited 16 times.
12. Mazumdar K, **Dutta NK**, Kumar KA, Dastidar SG: *In vitro* and *in vivo* synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains. *Biological & Pharmaceutical Bulletin* 28(4), 2005; 713-717. Impact factor 1.694, Cited 29times.

13. Basu LR, Mazumdar K, **Dutta NK**, Karak P, Dastidar SG: Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine. *Microbiological Research* 160, 2005; 95-100. Impact factor 2.777, Cited 36 times.
14. Na YR, Seok SH, Baek MW, Lee HY, Kim DJ, Noh KJ, Park SH, Lee HK, **Dutta NK**, Lee BH, Park JH: Enzyme-linked immunosorbent assay to detect the MHV infection in mice. *Laboratory Animal Research* 22(4), 2006; 433-435. Cited 1 time.
15. Mazumdar K, **Dutta NK**, Dastidar SG, Motohashi N, Shirataki Y: Effectiveness of the antiinflammatory drug diclofenac in the management of UTI caused by *E. coli*. *In Vivo* 20(5), 2006; 613-620. Impact factor 1.116, Cited 61 times.
16. Pal T, **Dutta NK**, Mazumdar K, Dasgupta A, Jeyaseeli L, Dastidar SG: Assessment of antibacterial activity of the cardiovascular drug nifedipine. *Oriental Pharmacy and Experimental Medicine* 6(2), 2006; 126-133. Cited 8 times.
17. Dastidar SG, Ganguly K, Mahapatra SK, **Dutta NK**, Mazumdar K, Chakrabarty AN, Motohashi N: Pronounced inhibitory effect of chlorcyclizine (CCZ) in experimental hepatocarcinoma. *In Vivo* 20, 2006; 97-102. Impact factor 1.116, Cited 2 times.
18. Jeyaseeli L, DasGupta A, Kumar KA, Mazumdar K, **Dutta NK**, Dastidar SG: Antimicrobial potentiality of thioxanthene flupenthixol through extensive *in vitro* and *in vivo* experiment. *International Journal of Antimicrobial Agents* 27, 2006; 58-62. Impact factor 4.253, Cited 18 times.
19. **Dutta NK**, Mazumdar K, Dastidar SG, Park JH: Activity of diclofenac used alone and in combination with streptomycin against *Mycobacterium tuberculosis* in mice. *International Journal of Antimicrobial Agents* 30(4), 2007; 336-340. Impact factor 4.253, Cited 64 times.
20. **Dutta NK**, Mazumdar K, Mishra US, Dastidar SG, Park JH: Isolation and identification of a flavonone from *Butea frondosa*. *Pharmaceutical Chemistry Journal* 41(5), 2007; 99-101. Impact factor 0.679, Cited 22 times.
21. DasGupta A, Jeyaseeli L, **Dutta NK**, Mazumdar K, Karak P, Dastidar SG, Motohashi N, Shirataki Y: Studies on the antimicrobial potential of the cardiovascular drug lacidipine. *In Vivo* 21(5), 2007; 847-850. Impact factor 1.116, Cited 32 times.
22. **Dutta NK**, Mazumdar K, Seok SH, Baek MW, Lee HY, Kim DJ, Noh KJ, Na YR, Park SH, Lee HK, Lee BH, Park JH: The anti-inflammatory drug diclofenac retains antilisterial activity *in vivo*. *Letters in Applied Microbiology* 47(2), 2008; 106-111. Impact factor 1.471, Cited 22 times.
23. Lee HK, Lee BH, **Dutta NK**, Seok SH, Baek MW, Lee HY, Kim DJ, Na YR, Noh KJ, Park SH, Kariwa H, Mai LQ, Heo SJ, Park JH: Detection of antibodies against SARS-coronavirus using recombinant truncated nucleocapsid proteins by ELISA. *Microbiology and Biotechnology* 18(10), 2008; 1717-1721. Impact factor 1.65, Cited 10 times.
24. **Dutta NK**, Mazumdar K, Lee BH, Baek MW, Kim DJ, Na YR, Park SH, Lee HK, Kariwa H, Mai LQ, Park JH: Search for potential target site of nucleocapsid gene for the design of an epitope based SARS DNA vaccine. *Immunology Letters* 118(1), 2008; 65-71. Impact factor 2.436, Cited 11 times.
25. Mishra US, **Dutta NK**[§], Mazumdar K, Mahapatra SK, Chakraborty P, Dastidar SG: Anti-*Salmonella* activity of a flavonone from *Butea frondosa* bark in mice. *Oriental Pharmacy and Experimental Medicine* 8(4), 2008; 339-348. [§]**Joint first authors**, Cited 10 times.
26. **Dutta NK**, Mazumdar K, Baek MW, Kim DJ, Noh KJ, Na YR, Park SH, Lee HK, Lee BH, Park JH: *In vitro* efficacy of diclofenac against *Listeria monocytogenes*. *European Journal of Clinical Microbiology and Infectious Diseases* 2(4), 2008; 315-319. Impact factor 2.537, Cited 14 times.
27. **Dutta NK**, Mazumdar K, DasGupta A, Dastidar SG: Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against *Mycobacterium tuberculosis* in mice. *Journal of Medical Microbiology* 58, 2009; 1667-1668. Impact factor 2.112, Cited 10 times.
28. Park SH, **Dutta NK**[§], Baek MW, Kim DJ, Na YR, Seok SH, Lee BH, Cho JE, Cho GS, Park JH: NaCl plus chitosan as a dietary salt to prevent the development of hypertension in spontaneously hypertensive rats. *Journal of Veterinary Science* 10(2), 2009; 141-146. PMCID: PMC2801110 [§]**Joint first authors**. Impact factor 1.327, Cited 13 times.

29. **Dutta NK**, Mazumdar K, DasGupta A, Dastidar SG: *In vitro* and *in vivo* efficacies of amlodipine against *Listeria monocytogenes*. *European Journal of Clinical Microbiology and Infectious Diseases* 7, 2009; 849-853. Impact factor 2.537, Cited 8 times.
30. Kim DJ, Seok SH, Baek MW, Lee HY, Na YR, Park SH, Lee HK, **Dutta NK**, Kawakami K, Park JH: Estrogen-responsive transient expression assay using a brain aromatase based reporter gene in zebrafish (*Danio rerio*). *Comparative Medicine* 59(5), 2009; 416-423. PMCID: PMC2771600. Impact factor 0.585, Cited 8 times.
31. **Dutta NK**, Mazumdar K, Park JH: *In vitro* synergistic effect of gentamicin with the anti-inflammatory agent diclofenac against *Listeria monocytogenes*. *Letters in Applied Microbiology* 48, 2009; 783-785. Impact factor 1.471, Cited 14 times.
32. Kim DJ, Seok SH, Baek MW, Lee HY, Na YR, Park SH, Lee HK, **Dutta NK**, Kawakami K, Park JH: Benomyl induction of brain aromatase and toxic effects in the zebrafish embryo. *Journal of Applied Toxicology* 29(4), 2009; 289-294. Impact factor 2.909, Cited 10 times.
33. Kim DJ, Seok SH, Baek MW, Lee HY, Na YR, Park SH, Lee HK, **Dutta NK**, Kawakami K, Park JH: Developmental toxicity and brain aromatase induction by high genistein concentrations in zebrafish embryos. *Toxicology Mechanisms and Methods* 19(3), 2009; 251-256. PMCID: PMC2739649. Impact factor 1.994, Cited 32 times.
34. Mehra S, Pahar B, **Dutta NK**, Conerly CN, Falkenstein KP, Alvarez X, Kaushal D: Transcriptional reprogramming in primate tuberculosis granulomas. *PLoS ONE* 5(8), 2010; e12266. PMCID: PMC2930844. Impact factor 2.766, Cited 81 times.
35. Mehra S, **Dutta NK**, Mollenkopf HJ, Kaushal D: MT2816 encodes a key *Mycobacterium tuberculosis* stress response factor. *Journal of Infectious Diseases* 202(6), 2010; 943-953. PMCID: PMC2862080. Impact factor 5.186, Cited 24 times.
36. **Dutta NK**, Mehra S, Didier PJ, Roy CJ, Doyle L, Alvarez XH, Ratterree M, Be NA, Lamichhane G, Jain SK, Lacey MR, Lackner AA, Kaushal D: Genetic requirements for the survival of tubercle bacilli in primates. *Journal of Infectious Diseases* 201(11), 2010; 1743-1752. PMCID: PMC3052882. Impact factor 5.186, Cited 125 times.
37. **Dutta NK**, Mehra S, Kaushal D: *Mycobacterium tuberculosis* sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. *PLoS ONE* 5(4), 2010; e10069. PMCID: PMC2851646. Impact factor 2.766, Cited 84 times.
38. DasGupta A, Chaki S, Mukherjee S, Jeyaseeli L, Mazumdar K, **Dutta NK**, Dastidar SG: Experimental analyses of synergistic combinations of antibiotics with a recently recognised antibacterial agent lacidipine. *European Journal of Clinical Microbiology and Infectious Diseases* 29(2), 2010; 239-243. Impact factor 2.537, Cited 11 times.
39. Lee HK, Lee BH, Seok SH, Baek MW, Lee HY, Kim DJ, Na YR, Noh KJ, Park SH, **Dutta NK**, Kariwa H, Nakauchi M, Heo SJ, Park JH: Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. *Journal of Veterinary Science* 11(2), 2010; 165-167. PMCID: PMC2873818. Impact factor 1.327, Cited 1 time.
40. Mehra S, Golden NA, **Dutta NK**, Doyle LA, Asher M, Russell-Lodrigue K, Monjure C, Didier PJ, Roy CJ, Blanchard JL, Veazey RS, Lackner AA, Kaushal D: Reactivation of latent tuberculosis in rhesus macaques by co-infection with simian immunodeficiency virus. *Journal of Medical Primatology* 40(4), 2011; 233-243. Impact factor 0.432, Cited 60 times.
41. **Dutta NK**, Illei PB, Peloquin CA, Pinn ML, Mdluli KE, Nuermberger EL, Grosset JH, Karakousis PC: Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. *Antimicrobial Agents and Chemotherapy* 56(7), 2012; 3726-3732. PMID: 22547623. Impact factor 4.255, Cited 33 times.
42. **Dutta NK**, Mehra S, Martinez AN, Alvarez XH, Renner NA, Morici LA, Pahar B, MacLean AG, Lackner AA, Kaushal D: Stress response factor sigH modulates the interaction of *Mycobacterium tuberculosis* with host phagocytes. *PLoS ONE* 7(1), 2012; e28958. PMCID: PMC3250399. Impact factor 2.766, Cited 46 times.

43. Roy CJ[§], Sivasubramani SK[§], **Dutta NK[§]**, Mehra S[§], Abrahams N, Killeen SZ, Hammoud BE, Talton JD, Didier P, Kaushal D: Aerosolized gentamicin reduces the burden of tuberculosis in a murine model. *Antimicrobial Agents and Chemotherapy* 56(2), 2012; 883-886. [§]**Joint first authors.** Impact factor 4.255, Cited 14 times.
44. **Dutta NK**, Alsultan A, Gniadek T, Belchis D, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC: Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. *Antimicrobial Agents and Chemotherapy* 57(8), 2013; 3910-3916. PMID: 23733473. Impact factor 4.255, Cited 25 times.
45. **Dutta NK**, Pinn ML, Zhao M, Rudek MA, Karakousis PC: Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis. *Journal of Antimicrobial Chemotherapy* 68(6), 2013; 1327-1330. Impact factor 5.3, Cited 19 times.
46. **Dutta NK**, Abdullah Alsultan, Peloquin CA, Karakousis PC: Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. *Antimicrobial Agents and Chemotherapy* 57(3), 2013; 1535-1537. PMID: 23295923. Impact factor 4.255, Cited 14 times.
47. **Dutta NK**, Karakousis PC: PA-824 is as effective as isoniazid against latent TB infection in C3HeB/FeJ mice. *International Journal of Antimicrobial Agents* Impact factor 44(6), 2014; 564-566. Impact factor 3.53, Cited 5 times.
48. **Dutta NK**, Pinn ML, Karakousis PC: Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine TB. *Antimicrobial Agents and Chemotherapy* 58 (9), 2014; 5567-5569 Impact factor 4.255. Cited 16 times.
49. **Dutta NK**, Pinn ML, Karakousis PC: Reduced emergence of isoniazid resistance with concurrent use of thioridazine against acute murine Tuberculosis. *Antimicrobial Agents and Chemotherapy* 58 (7), 2014; 4048-4053 Impact factor 4.255, Cited 24 times.
50. **Dutta NK**, Illei PB, Jain SK, Karakousis PC: Characterization of a novel necrotic granuloma model of latent tuberculosis infection and reactivation in mice. *American Journal of Pathology* 184 (7), 2014; 2045-2055. Impact factor 4.069. **Highlighted in "This month in AJP" 184 (7), 2014; 1911**, Cited 24 times.
51. **Dutta NK**, Bandyopadhyay N, Veeramani B, Lamichhane G, Karakousis PC, Bader J: Systems biology prediction and validation of genes required for *Mycobacterium tuberculosis* persistence in mammalian lung. *mBIO* 5(1), 2014; e01066-13. Impact factor 6.689, Cited 15 times.
52. **Dutta NK**, McLachlan, Mehra S, Kaushal D: Lung Responses to *Mycobacterium Tuberculosis* Infection in a Primate Model of Protection. *Trials in Vaccinology* 3, 2014; 47-51. Cited 11 times.
53. Via LE, Savic R, Weiner D, Zimmerman M, Prideaux B, Irwin S, O'Brien P, Gopal P, Eum S, Lee M, Lanoix JP, Lenaerts A, Dutta NK, Karakousis PC, Nuermberger E, Barry CE, Dartois V. Pharmacokinetics, host-mediated bioactivation of pyrazinamide: implications for emergence of resistance, and therapeutic alternatives. *ACS Infectious Diseases* 8;1(5), 2015:203-214. Impact factor 4.325, Cited 38 times.
54. **Dutta NK**, He R, Pinn M, He Y, Burrows F, Zhang ZY, Karakousis PC. Mycobacterial Protein Tyrosine Phosphatases A and B Inhibitors Augment the Bactericidal Activity of the Standard Anti-tuberculosis Regimen. *ACS Infectious Diseases* 2 (3), 2016:231–239, Impact factor 4.325, Cited 10 times.
55. **Dutta NK**, Pinn ML, Zimmerman MD, Prideaux B, Bruiners N, Dartois V, Gennaro ML, Karakousis PC. Statin adjunctive therapy shortens the duration of tuberculosis treatment in mice. *Journal of Antimicrobial Chemotherapy*, 71 (6), 2016: 1570-1577. Impact factor 5.217, Cited 22 times.
56. Chuang YM, **Dutta NK**, Hung CF, Wu TC, Rubin H, Karakousis PC. The stringent response factors PPX1 and PPK2 play an important role in *Mycobacterium tuberculosis* metabolism, biofilm formation, and sensitivity to isoniazid in vivo. *Antimicrobial Agents and Chemotherapy* 60 (11), 2016; 6460-6470 Impact factor 4.255, Cited 11 times.
57. **Dutta NK**, Pinn ML, Karakousis PC. Metformin adjunctive therapy does not improve the sterilizing activity of the first-line antitubercular regimen in mice. *Antimicrobial Agents and Chemotherapy* 61 (8), 2017; e00652-17. Impact factor 4.255, Cited 4 times.

58. Aggarwal A, Parai MK, Shetty N, Wallis D, Woolhiser L, Hastings C, **Dutta NK**, Galaviz S, Dhakal RC, Shrestha, R, Wakabayashi S, Walpole C, Matthews D, Floyd D, Scullion P, Riley J, Epemolu O, Norval S, Snaveley T, Robertson GT, Rubin EJ, Ioerger TR, Sirgel EA, van der Merwe R, van Helden PD, Keller P, Böttger EC, Karakousis PC, Lenaerts A.J, Sacchettini JC. Development of a novel lead that targets M. tuberculosis polyketide synthase 13. *Cell* 170 (2), 2017, 249-259. Impact factor 31.398, Cited 29 times.
59. **Dutta NK**, Klinkenberg LG, Vazquez M-J, Segura-Carro D, Colmenarejo G, Ramon F, Rodriguez-Miquel B, Mata L, Francisco EP, Chuang Y-M, Rubin H, Lee JJ, Eoh H, Bader JS, Perez-Herran E, Mendoza-Losana A, Karakousis PC. Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence. *Science Advances* 5(3), 2019, eaav2104. Impact factor 11.51
60. **Dutta NK**, Bruiners N, Zimmerman MD, Tan S, Dartois V, Gennaro MKL, Karakousis PC. Adjunctive host-directed therapy with statins improves tuberculosis-related outcomes in mice. *Journal of Infectious Diseases* 2019 (in press). Impact factor 5.186.

Review Articles:

61. **Dutta NK**, Mazumdar K, Park JH, Dastidar SG, Kristiansen JE, Molnar J, Amaral L: The potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium. *International Journal of Antimicrobial Agents* 30(3), 2007; 242-249. Impact factor 4.253, Cited 76 times.
62. Mazumdar K, Dastidar SG, Park JH, **Dutta NK**[§]: The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. *European Journal of Clinical Microbiology and Infectious Diseases* 28(8), 2009; 881-891. [§]**Corresponding author**. Impact factor 2.537, Cited 48 times.
63. Mazumdar K, Kumar AK, **Dutta NK**[§]: Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. *International Journal of Antimicrobial Agents* 36(4), 2010; 295-302. [§]**Corresponding author**. Impact factor 4.253, Cited 21 times.
64. **Dutta NK**, Mazumdar K, Dastidar SG, Karakousis PC, Amaral L: New patentable use of an old neuroleptic compound thioridazine to combat tuberculosis: A Gene Regulation Perspective. *Recent Patents on Anti-Infective Drug Discovery* 6(2), 2011; 127-137. Cited 30 times.
65. **Dutta NK**, Karakousis PC: Latent tuberculosis infection: myths, models, and molecular mechanisms. *Microbiology, Molecular Biology Reviews* 78(2), 2014; 343-371. Impact factor 14.61. Cited 94 times.
66. **Dutta NK**[§], Karakousis PC: Thioridazine for treatment of tuberculosis: Promises and pitfalls. *Tuberculosis (Edinb)* 94(6), 2014; 709-711. [§]**Corresponding author**. Impact factor 2.727. Cited 6 times.
67. **Dutta NK**[§], Karakousis PC: Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin? *Front. Microbiol.* 2015 Oct 14; 6: 1117. [§]**Corresponding author**. Impact factor 4.019. Cited 5 times.
68. Sharma S, **Dutta NK**[§]: Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates. *Front. Microbiol.* 2017 Nov 27; 8: 2274. [§]**Corresponding author**. Impact factor 4.019. Cited 0 times.
69. Frank DJ, Horne DJ, **Dutta NK**, Shaku MT, Madensein R, Hawn TR, Steyn AJ, Karakousis PC, Kana BD, Meintjes G, Laughon B, Tanvir Z. Remembering the Host in Tuberculosis Drug Development. *Journal of Infectious Diseases* 2018 (in press). Impact factor 5.186.

Book Chapters

70. Antimicrobial Drug Resistance, **Dutta NK**, Karakousis PC. Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Switzerland: Springer International Publishing; 2017. Chapter 25, Mechanisms of Action, Resistance of the Antimycobacterial Agents; p.359-383. 770p. Cited 1 time.

71. Handbook of Tuberculosis, Karakousis PC, **Dutta NK**, Manabe YC. Grosset JH, Chaisson RE, editors. Switzerland: Springer International Publishing; 2017. Chapter 2, Clinical Features and Diagnosis of Tuberculosis: Primary Infection and Progressive Pulmonary Tuberculosis; p.17-34. 221p. Cited 1 time.

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles

72. Levine DM, **Dutta NK**, Scanga CA, Mehra S, Stein CM, Kaushal D, Karakousis PC, Salamon H: An Ontology for TB Systems Biology. *Tuberculosis* 2015. Impact factor 2.727. Cited 4 times.

Editorials

73. **Dutta NK**, Karakousis PC: Tuberculosis (TB) Chemotherapy: Present situation, possible solutions, and progress towards a TB-free world. *Indian Journal of Medical Microbiology* 30(3), 2012; 261-263. Impact factor 1.157. Cited 9 times.
74. Thombre R, Jangid K, Shukla R and **Dutta NK** (2019) Editorial: Alternative therapeutics against antimicrobial-resistant pathogens. *Front. Microbiol.* 10:2173. doi: 10.3389/fmicb.2019.02173

Inventions, Patents, Copyrights (pending):

Date Title

- 2005 The potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug Diclofenac sodium (Application No. 346/Kol/2005) published in the official journal of the patent office (ISSUE NO. 42/2009 FRIDAY DATE: 16/10/2009), India.
[http://ipindia.nic.in/ipr/patent/journal_archieve/journal_2009/pat_arch_102009/official_journal_16102009_part_i.pdf]
- 2014 Lipid-modulating Agents as Adjunctive Therapy for Tuberculosis (JHU ref# C12760)
- 2015 A Novel Shock and Kill Strategy for Targeting Bacterial Persisters" (JHU#C13809)
- 2016 Stringent-response DNA vaccine (SR Vaccine) enhances the anti-tubercular activity of the first-line regimen. (JHU#D14044)

Extramural Sponsorship (current, pending, previous)

Current

09/23/2019 - 8/22/2021

Regional Prospective Observational Research for Tuberculosis (RePORT) International & CFAR: 218992

Karakousis and Dutta (PI)

Blood based biomarker for predicting treatment failure

This proposal will use multiple high-throughput modalities, including LC-MS/MS and RNA-seq, to detect biomarkers associated with treatment failure.

Role: Co-PI, percent effort: 1.44 cal months

09/1/17-8/31/20

UH3 AI122309 (Karakousis), NIH/NIAID

Karakousis (PI)

Statins as Adjunctive, Host-Directed Therapy for TB

The goal of this study is to investigate the potential role of pravastatin as adjunctive, host-directed therapy for TB.

The primary outcomes of this prospective randomized clinical study will be median time to sputum culture conversion and proportion of sputum sample conversion at 8 weeks following treatment.

Role: Co-investigator /Research project coordinator, Total direct cost: \$879,612, percent effort: 12 cal months

01/1/19 – 12/31/2024

R01HL149450, NHLBI

Gennaro/ Karakousis (PI)

Foam cells as drug targets in TB

The overall objective of this proposal is to discover druggable targets in the pro-lipogenic and anti-lipogenic pathways, with the long-term goal of shortening the duration of TB treatment and improving TB-related immunopathology

Role: Co-investigator, percent effort: 6 cal months

01/01/2019 - 12/31/2024

K24AI143447-01A1, NIAID

Karakousis (PI)

Advancing Host-Directed Therapies for Tuberculosis

Using clinical samples from a randomized study of HIV-infected and HIV-uninfected persons receiving pravastatin as adjunctive therapy for TB, we will determine how statins help kill TB germs and identify blood biomarkers predictive of TB treatment outcome.

Role: Co-investigator /Program coordinator, percent effort: 2.4 cal months

Pending

Extramural

04/01/2020 - 03/31/2022

R21AI151592, NIAID

Dutta (PI)

Exploring sex-based differences in response to host-directed therapy for TB

In the current study, we will determine whether statins are differentially effective against TB in both sexes of mice and in primary macrophages from men and women.

Role: PI, percent effort: 4.8 cal months

03/01/2020 - 02/28/2025

R01AI152147, NIAID

Dutta, Karakousis, Singh

Small Molecule Biosignature to Predict Reactivation of LTBI in HIV

In the current proposal, we will collect blood from HIV-infected adults and children before and after TB treatment, and use several cutting-edge techniques to identify a set of biomarkers, whose presence in the blood portends reactivation of TB infection, and which can be followed to assess the adequacy of treatment.

Role: PD/PI, percent effort: 6 cal months

Previous

12/01/16-12/31/18

CFAR Scholar Grants for Faculty Development

Dutta (PI)

miRNA biosignature to diagnose active TB in HIV-infected individuals

This study will investigate the hypothesis that TB induces unique changes in the metabolism and inflammatory state of the HIV-infected host, which can be used for TB diagnosis.

Role: PI, Total direct cost: \$50,000, percent effort: 2.4 cal months

07/01/17 -06/30/18- ICTR Nexus Biomarkers and Diagnostic award

Dutta (PI)

Evaluation of a serum biosignature for identifying HIV-infected individuals at greatest risk for developing active TB

Role: PI, Total direct cost: \$25,000, percent effort: 2.4 cal months

09/01-17- 08/31/18

AIDS CLINICAL TRIALS GROUP

Dutta (PD/PI)

Evaluation of a serum biosignature for identifying HIV-infected individuals at greatest risk for developing active TB
We propose to discover novel host metabolites and miRNA biomolecule signatures that could serve as new correlates of TB risk.

Role: PD/PI, Total direct cost: \$136,000, percent effort: 2 cal months

07/01/15-06/30/18

1R21AI114507 NHLBI

Karakousis (PI)

Validation of RelA as a Target for Mycobacterium Tuberculosis Persisters

The goal of this study is to provide proof of concept that inhibition of the Mtb enzyme RelA leads to increased bacterial killing under stress conditions *in vitro* and *in vivo*, as well as increased susceptibility to first-line anti-TB drugs.

Role: Co-investigator, Total direct cost: \$125,000, percent effort: 1.8 cal months

12/01/15-11/30/18

R21 AI122922-01 NIH/NIAID

Karakousis (PI)

A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient host

The objective of this study is to determine if the Mtb stringent response is required for bacterial persistence in the CD4 T-cell-deficient host, and whether this pathway can be targeted by specific inhibitors, thereby enhancing the activity of the first-line drug regimen.

Role: Co-investigator, Total direct cost: \$150,000, percent effort: 4 cal months

2014/12/01-2017/11/30

OPP1116944, Bill and Melinda Gates Foundation

Sigal, Alex (PI)

Quantitative assessment of the tipping point in *Mycobacterium tuberculosis* transmission and infection

Quantitative methods will be used to study Mtb dynamics to determine the tipping point for macrophage infection, which depends on the number and state of internalized bacteria and leads to either control of infection or uncontrolled Mtb replication

Role: Co-investigator, Total direct cost: \$216,264, percent effort: 4.2 cal months

09/01/15-8/31/17

1UH2AI122309 NIH/NIAID

Karakousis (PI)

Statins as Adjunctive, Host-Directed Therapy for TB

The goal of this study is to investigate the potential role of statins as adjunctive, host-directed therapy for TB. Preclinical studies in relevant *in vitro* and animal models will inform selection of statin and dosing for a prospective, randomized clinical study. The primary outcomes will be median time to sputum culture conversion and proportion of sputum sample conversion at 8 weeks following treatment.

Role: Co-investigator /Research project coordinator, Total direct cost: \$437,540, percent effort: 9 cal months

2014/12/01-2015/11/30

UM1AI068636, AIDS Clinical Trial Group Network

Flexner/Karakousis (PI)

Lipid-modulating agents as HDT for tuberculosis

This study will investigate the utility of the lipid-lowering agents, statins, as adjunctive, host-directed therapy for tuberculosis in macrophage models and in preliminary mouse studies. Global gene expression will be used to begin to explore their antitubercular mechanism of action.

Role: PDC, Total direct cost: \$219,040, percent effort: 6 cal months

10/14/15-11/13/16

Texas A and M (Karakousis)

Testing the anti-TB activity of COMPOUND X in mice

The objective of this study is to test the antitubercular activity of three different compounds relative to the first-line drug, isoniazid, against acute TB infection in the standard mouse model.

Role: PDC, Total direct cost: \$17,544, percent effort: 2 cal months

08/02/13-07/31/15

90060034 Aarden Pharmaceuticals Inc.

Karakousis (PI)

Testing the Anti-TB Activity of PTP Inhibitors in Guinea Pigs

The objective of this study is to determine the antitubercular activity of inhibitors targeting mycobacterial protein tyrosine phosphatase in the guinea pig model of TB infection.

Role: PDC, Total direct cost: \$43,158, percent effort: 3 cal months

2010/09/01-2014/08/31

R01HL106786, NIH/NHLBI

Karakousis, Petros (PI)

A Multidisciplinary Approach to Understanding TB Latency and Reactivation

This study used a systems biology-based approach to identify host cytokine networks and Mtb molecular pathways required for latent TB infection and reactivation

Role: PDC

2010/09/17-2013/09/16

U18FD004004-01, FDA

Mdluli, Khisimuza (PI)

Qualifying New Pre-Clinical Models for the Development of Tuberculosis Drugs

This study addressed the hypothesis that that tissue necrosis is a critical determinant of M. tuberculosis persistence by comparing outcomes of experimental chemotherapy in animal models with and without necrotic granulomas

Role: PDC

EDUCATIONAL ACTIVITIES

Teaching

Classroom instruction (dates, course title, role, location)

2004 - 2006 Introduction to microbial world and bacteriology for B.Sc. (H) Microbiology-3-year full-time programme (Six- Semester Course), Lecturer, Institute of Genetic Engineering, Kolkata, India

Training and supervising research team

Short-Term Trainees/High school students:

06/11-08/11 Ben Roytenberg, West Baltimore High

07/15- 07/16 Jennifer Mendez, Baltimore Polytechnic Institute

Summer students:

6/16- 8/16 Keyane Haile, Meharry Medical College

6/16- 8/16 Shreya Rangarajan, Olin College of Engineering '18

6/16- 8/16 Christina Blonski (DSIP/JHSPH student)

Undergraduate Students:

4/15- 4/17 Sameer Thakkar, JHU
 4/16- 4/18 Grace Ren, JHU
 03/17-05/17 Rachel Lorenc, JHU
 09/17-present Sarah Kohl, JHU
 Masters Student:
 10/16- 10/18 Alysha Ellison, MPH student, Johns Hopkins Bloomberg School of Public Health
 Graduate student's rotation:
 9/15- 12/15 Lionel Chia, Rotation, JHUSOM
 9/16- 12/16 Monika Looney, Rotation, JHUSOM
 01/17-3/17 Daymond Parrilla, JHUSOM
 09/19-12/17 Stephanie Myers, Department of Molecular and Comparative Pathobiology, JHUSOM

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments (date, committees)

1998-1999 President, Students' Organization, School of Science, Visva Bharati University, India – A prestigious body where IK Gujral, then Prime Minister of India and Chancellor of Visva Bharati University was one of the members
 2004-2006 Teacher in charge, Institute of Genetic Engineering, University of Kalyani (Presently affiliated to West Bengal University of Technology), Kolkata, India
 2004-2006 Member Governing body, Institute of Genetic Engineering, University of Kalyani (Presently affiliated to West Bengal University of Technology), Kolkata, India
 2011-2012 Member, Scientific Committee, Johns Hopkins Postdoctoral Association
 2018 Judge, 10th Annual Medical Student Research Symposium, 02/09/2018, Johns Hopkins School of Medicine
 2019 Judge, 11th Annual Medical Student Research Symposium, 02/08/2019, Johns Hopkins School of Medicine

Editorial Activities (Member in Board of)

Date Journals
 2011-present African Journal of Pharmacy and Pharmacology
 2011-2015 World Journal of Clinical Infectious Diseases (<http://www.wjgnet.com>)
 2011-2015 Clinical Reviews and Opinions (www.academicjournals.org/CRO)
 2011-present WebmedCentral *plus* Infectious Diseases (www.webmedcentral.com/plus/speciality.../Infectious_diseases)
 2013-present Review Editor, Frontiers in Antimicrobials, Resistance and Chemotherapy (<http://www.frontiersin.org>)
 2013-present American Journal of Microbiological Research (<http://www.sciepub.com/journal/ajmr/EditorialBoard>)
 2013-present International Board member, The International Arabic Journal of Antimicrobial agents (<http://www.iajaa.org>)
 2013-present Advances in Medicine (www.hindawi.com/journals/amed/editors/infectious.diseases)
 2015-present Austin Tuberculosis: Research & Treatment (<http://www.austinpublishinggroup.com>)
 2015-present Journal of Vaccines Research & Vaccination (<http://www.heraldopenaccess.us/journals/Vaccines-Research-&-Vaccination/editorial-board.php>)
 2016-present Journal of Bacteriology & Mycology Open Access (<http://medcraveonline.com/JBMOA/editorial-board>)
 2016-present SOJ Microbiology & Infectious Diseases (<http://www.symbiosisonlinepublishing.com/microbiology-infectiousdiseases/editorialboard.php>)
 2016-present EC Proteomics and Bioinformatics, https://www.econicon.com/editorial_popup.php?id=3808

2017-present Guest Associate Editor for Antimicrobials, Resistance and Chemotherapy, Frontiers in Microbiology journal for a research topic on “**Alternative therapeutics against antimicrobial-resistant pathogens**”.
<http://journal.frontiersin.org/researchtopic/5880/alternative-therapeutics-against-antimicrobial-resistant-pathogens>

Journal peer review activities (<https://publons.com/researcher/799937/noton-k-dutta/>)

[Reviewed for 14 journals, 91 Pre-Publication Reviews, 15 Editor merit]

2014-present BBA - General Subjects
 2010-present PLoS One
 2011-present International Journal of Antimicrobial Agents
 2011-present Indian Journal of Medical Microbiology
 2012-present Anti-Infective Agents
 2013-present Mycobacterial Diseases: Tuberculosis and Leprosy
 2013-present Current Genomics
 2013-present Journal of Clinical Microbiology
 2013-present Antimicrobial Agents and Chemotherapy
 2013-present Journal of Infectious Diseases and Immunity
 2014-present Tuberculosis
 2015-present Scientific reports
 2017-present BMC Complementary and Alternative Medicine

Grant Review groups

September 2013-Reviewer (Confirmation Number: 49792042-248960), The South African Medical Research Council (MRC)

September 2013-Reviewer (Refereence#13259), The Dutch Technology Foundation STW, Netherlands

May 2018-Reviewer, 2018 Peer Review Medical Research Program (PRMRP) for the Department of Defense.
 Topic Area(s) of Expertise: Non-Viral Emerging Infectious Diseases; Tuberculosis

Professional Societies

Date	Organization
2004-	Life Member, International Society of Non-antibiotics (ISN)
2004-	Life Member, Asian Network of Research on Antidiabetic Plants (ANRAP)
2004-	Life Member, Indian Association of Medical Microbiologists (IAMM)
2004-	Life Member, Association of Microbiologists of India (AMI)
2004-	Life Member, Hospital Infection Society of India (HIS)
2004-2010	Member, International Society for Infectious Diseases (ISID)
2008-present	Member, American Society for Microbiology (ASM)
2012-present	Member, American Thoracic Society (ATS)
2013-present	Member, International Union against Tuberculosis and Lung Disease (IUATLD)
2017-present	Board member, International Society of Non-Antibiotics (ISN) http://www.non-antibiotics.com/

RECOGNITION

Fellowships:

2001-2004 Research Fellowship from Department of Science and Technology, Govt. of West Bengal, India
 2006-2008 Postdoctoral Fellowship at Seoul National University funded by Korea Research Foundation
 2008-2011 Postdoctoral Fellowship at Tulane National Primate Research Center funded by National Institutes of Health
 2011-2015 Postdoctoral Fellowship at Johns Hopkins University School of Medicine funded by National Institutes of Health

Awards:

2000	Visva Bharati University (NCERT, Govt. of India) Merit Scholarship for obtaining 2 nd rank (with 75% marks) in Bachelor of Education
2005	Best poster award from Indian Association of Medical Microbiologists, West Bengal Chapter, Kolkata, India
2005	Dr. A.N. Chakrabarty Memorial Gold Medal for the best published paper in Mycobacteriology from Indian Association of Medical Microbiologists
2005	Best paper award from 12 th West Bengal State Science and Technology Congress, Kolkata, India
2010	Tulane Center for Infectious Disease Travel Award
2012	Basic Research Postdoctoral Fellow Award Nominee, JHU Dept. of Medicine
2013	Poster Award, Johns Hopkins University Postdoctoral Association Symposium, 2013
2013	Basic Research Postdoctoral Fellow Award Nominee, JHU Dept. of Medicine
2014	Arthur M. Dannenberg, Jr. Award for Postdoctoral Research, 2014
2014	Dr. Dutta's work was featured in a July 2014 Journal of American Pathology, "This Month in AJP"
2015	Johns Hopkins University Center for AIDS Research Tangible Research Initiative award
2016	Speaker, Keystone Symposia on Tuberculosis Co-Morbidities and Immunopathogenesis http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1411
2016	Finalist for the W. Leigh Thompson Excellence in Research: Basic Research Faculty Award
2007	Facilitator, ASM Microbe 2016 (June 16–20, 2016, Boston, MA), Peer-to-peer Exchange Program on Host directed tuberculosis therapy.
2017	Runner-up for the W. Leigh Thompson Excellence in Research: Basic Research Faculty Award, Johns Hopkins Department of Medicine 2017 Research Retreat Committee
2017	Travel Scholarship Recipient: Summer Institutes, Dept. of Biostatistics, University of Washington
2018	Finalist for the W. Leigh Thompson Excellence in Research: Basic Research Faculty Award
2019	Finalist for the W. Leigh Thompson Excellence in Research: Basic Research Faculty Award

Invited Talks

2005	"Antimycobacterial activity of methdilazine, an antimicrobial phenothiazine", 12 th West Bengal State Science and Technology Congress, Kolkata, India
January 14, 2008	"Search for potential target site of nucleocapsid gene for the design of an epitope based SARS DNA vaccine" Seoul National University-Hokkaido University joint symposium, Seoul, Korea
November 21, 2008	" <i>Mycobacterium tuberculosis</i> gene expression in response to the antimycobacterial phenothiazine thioridazine", Louisiana Vaccine Center Symposium on Mycobacteria, Tuberculosis, Host Defense, LSU School of Medicine, New Orleans, LA
June 15, 2012	Annual Scientific Meeting at Johns Hopkins Center for TB Research
June 6, 2013	Annual Scientific Meeting at Johns Hopkins Center for TB Research
June 13, 2014	Annual Scientific Meeting at Johns Hopkins Center for TB Research
Feb 29, 2016	Keystone Symposia on Tuberculosis Co-Morbidities and Immunopathogenesis
June 21, 2016	Annual Scientific Meeting at Johns Hopkins Center for TB Research

Recent conference attended /Abstract /Poster presentation

1. The "reduced immunopathology" phenotype exhibited by the *Mycobacterium tuberculosis* $\Delta\sigma^H$ mutant appears to be conserved in an aerosol infection based nonhuman primate model of TB. Mehra S, Gambhira R, **Dutta NK**, Roy CJ, Singletary M, Blanchard L, Conerly C, Pahar B, LeBreton SL, Alvarez X, Aye PP, Didier PJ, Kuroda M, Lackner AA, Kaushal D. NIH center of Biomedical Research Excellence (COBRE) - Infectious disease and immunology symposium. May 13, 2008• Tulane National Primate Research Center, Covington, USA
2. Discovery of genes essential for survival and persistence of *Mycobacterium tuberculosis* in a nonhuman primate model of TB. **Dutta NK**, Mehra S, LeBreton SL, Lamichhane G, Jain SK, Roy CJ, Didier P, Xavier A, Doyle L, Lackner AA, Kaushal D. Tuberculosis: Biology, Pathology and Therapy, January 25 - 30, 2009• Colorado, USA

3. Modulation of host-pathogen interaction by the *Mycobacterium tuberculosis* stress response factor SigH. Mehra S, **Dutta NK**, Lackner AA, Kaushal Deepak. Tuberculosis: Biology, Pathology and Therapy, January 25 - 30, 2009• Colorado, USA
4. *Mycobacterium tuberculosis* gene expression in response to the antimycobacterial phenothiazine thioridazine. **Dutta NK**, Mehra S, LeBreton SL, Kaushal D. 109th American Society for Microbiology General Meeting, May 17, 2009• Philadelphia, USA
5. Aerobiological characteristics of multisized Mycobacterial bioaerosols in a nonhuman primate model of pulmonary tuberculosis. Sivasubramani SK, Kaushal D, **Dutta NK**, Killeen S, Roy CJ. Aerobiology in Bio-Defence conference, July 13-16, 2009• Cumberl, USA
6. New use of old drugs in the fight against TB. **Dutta NK**, Mehra S, Abrahams N, Sivasubramani SK, Nallapaneni A, Killeen SZ, Macfarl, JF, Didier PJ, Roy CJ, Kaushal D. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12, 2010• Boston, USA
7. Stress response factor sigh modulates the interaction of *Mycobacterium tuberculosis* with host phagocytes. Dutta NK, Mehra S, Conerly C, Alvarez X, Kaushal D. Louisiana NCRR/IDeA 2010 Biomedical Research Symposium. Jan 22, 2010• Baton Rouge, USA
8. Computational modeling of genetic requirements for *Mycobacterium tuberculosis* persistence in vivo, experimental validation in murine lungs. Dutta NK, Veeramani B, Lamichhane G, Bader J, Karakousis PC. 112th American Society for Microbiology General Meeting, June 16, 2012• San Francisco, USA
9. Computational modeling of genetic requirements for *mycobacterium tuberculosis* persistence in vivo and experimental validation in murine lungs. **Dutta NK**, Veeramani B, Lamichhane G, Bader J, Karakousis PC. Department of Medicine 2012 Assessment Retreat, Johns Hopkins Broadway Campus, April 23, 2012• Baltimore, USA
10. Dramatic efficacy of the novel three-drug regimen PaMZ (PA-824/moxifloxacin/pyrazinamide) against chronic tuberculosis infection in guinea pigs. **Dutta NK**, Belchis D, Peloquin C, Nuermberger EL, Mdluli K, Karakousis PC. American Thoracic Society International Conference. May 17, 2013• Philadelphia, USA.
11. A novel paucibacillary model of TB infection using C3HeB/FeJ mice. **Dutta NK**, Illei PB, Pinn ML, Jain SK, Karakousis PC. Department of Medicine 2013 Assessment Retreat, Johns Hopkins Broadway Campus, April 10, 2013• Baltimore, USA.
12. A novel paucibacillary model of latent TB infection using C3HeB/FeJ mice. **Dutta NK**, Illei PB, Pinn ML, Jain SK, Karakousis PC. Host Response in Tuberculosis, January, 2013• British Columbia, Canada.
13. Comparative pharmacokinetics of repeated doses of rifampin and rifapentine in guinea pigs. Pinn ML, **Dutta NK**, Sultan A, Peloquin CA, Karakousis PC. Host Response in Tuberculosis, January, 2013• British Columbia, Canada.
14. Ontology for TB Systems Biology. Levine DM, Scanga CA, Mehra S, Stein CM, **Dutta NK**, Kaushal D, Karakousis PC, Salamon H. Host Response in Tuberculosis, January, 2013• British Columbia, Canada.
15. Statin adjunctive therapy shortens the duration of tuberculosis treatment in mice. **Dutta NK**, Pinn ML, Zimmerman MD, Prideaux B, Bruiners N, Dartois V, Gennaro ML, Karakousis PC. ASM's Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and ISC's International Congress of Chemotherapy (ICC), September 17, 2015• San Diego, USA
16. Pravastatin Therapy Augments Bactericidal Activity of the First-line Tuberculosis Regimen In Vivo. **Dutta NK**, Pinn ML, Zimmerman MD, Prideaux B, Bruiners N, Dartois V, Gennaro ML, Karakousis PC. ASM Microbe 2016 in Boston, Massachusetts, June 16 - 20, 2016.
17. Role of the host Mevalonate Pathway in Mycobacterium tuberculosis infection. Bruiners N, Salamon H, **Dutta NK**, Dartois V, Karakousis PC, Gennaro ML. First Line of Defense: Protective Immunity at Barrier Surfaces, Rutgers New Jersey Medical School, September 13-14, 2016
18. Pravastatin Adjunctive Therapy for Tuberculosis Reduces IL-6 in the Lungs and Serum of Mice. **Dutta NK**, Pinn ML, Zimmerman MD, Prideaux B, Bruiners N, Dartois V, Gennaro ML, Karakousis PC. ASM Microbe 2017 in New Orleans, LA, June 1 - 5, 2017.
19. Role of the host Mevalonate Pathway in Mycobacterium tuberculosis infection. Bruiners N, Salamon H, Dutta NK, Dartois V, Karakousis PC, Gennaro ML. ASM Conference on Tuberculosis: Past, Present and Future, New York Marriott at the Brooklyn Bridge, April 1-4, 2017